Investor Presentaiton

Financial Performance 2Q/FY24 Q2 recovery; Demand uptrend intact 2Q/FY24 Consolidated Financials [*Crore] 1Q/FY24 2Q/FY24 1 2Q/FY23 Y-o-Y Q-o-Q ■ Revenues: Revenues 1,182 1,224 Gross Margins 50.6% 52.5% 1,576 55.1% EBITDA 168 188 449 -22% 4% -260bps 190bps -58% 12% % to Revenues 14.2% 15.4% 28.5% PBT 41 54 328 Net Profit 25 37 233 -1310bps -84% -84% 120bps 32% 48% Comments 1,224 Cr, declined 22% YoY, particularly from strong CDMO- Synthesis revenues in base year, however quarter-to-quarter recovered in-line with improving API and FDF revenues Underlying revenues increased by 18% YoY ex-large PO supplies ■ Gross Margins: 52.5%, decreased by 260 bps YoY and increased by 190 bps QoQ due to change in product mix ■ R & D spends reported at 58 crs and ~4.7% of Revenues; higher spends partly due to additional initiative in CGT space % to Revenues EPS 2.1% 3.0% 14.8% ■ EBITDA : 188 Cr, decreased by 58% YoY and increased by 12 % QoQ 0.5 0.6 4.3 -86% 20% 1 15 ■ EBITDA Margins: 15.4%, due to negative operating leverage though expanded 120bps QoQ ■ Net Profits: 37 Cr 2Q FY24 results includes 1) Cell & Gene related spends of 6 Cr under R&D expenses, 2) ImmunoACT share of loss 2.1 Cr and 3) LSPL Unit 2 expenses 5 Cr Laurus Q2 & H1 FY 2024 Investor Presentation | October 20, 2023 LAURUS Labs Knowledge. Innovation. Excellence

View entire presentation